Natixis Advisors LLC Buys 4,321 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Natixis Advisors LLC increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 29.4% during the 2nd quarter, Holdings Channel reports. The fund owned 19,005 shares of the company’s stock after buying an additional 4,321 shares during the quarter. Natixis Advisors LLC’s holdings in Structure Therapeutics were worth $746,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of GPCR. Boxer Capital LLC acquired a new stake in Structure Therapeutics in the fourth quarter worth $16,304,000. Avoro Capital Advisors LLC raised its holdings in Structure Therapeutics by 133.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after buying an additional 1,333,333 shares during the period. Octagon Capital Advisors LP acquired a new stake in shares of Structure Therapeutics during the fourth quarter worth $16,875,000. Bellevue Group AG lifted its position in Structure Therapeutics by 2,858.7% in the 1st quarter. Bellevue Group AG now owns 363,926 shares of the company’s stock valued at $15,598,000 after acquiring an additional 351,626 shares in the last quarter. Finally, Capital International Investors acquired a new position in Structure Therapeutics in the 4th quarter worth $34,647,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $40.29 on Friday. The stock has a 50 day moving average price of $38.06 and a 200 day moving average price of $39.73. The stock has a market capitalization of $1.88 billion, a PE ratio of -52.32 and a beta of -3.52. Structure Therapeutics Inc. has a 52 week low of $26.61 and a 52 week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. As a group, research analysts forecast that Structure Therapeutics Inc. will post -0.86 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on GPCR. JMP Securities dropped their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. BMO Capital Markets lifted their target price on Structure Therapeutics from $83.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday, June 7th. JPMorgan Chase & Co. initiated coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an “overweight” rating and a $65.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $84.63.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.